In the PARAMOUNT ( `` A Phase @ , Double-Blind , Placebo-Controlled Study of Maintenance Pemetrexed plus Best Supportive Care vs. Best Supportive Care Immediately Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-Squamous Non-Small-Cell Lung Cancer '' ) trial , patients with advanced nonsquamous non-small-cell lung cancer ( NS-NSCLC ) benefited from pemetrexed maintenance therapy after induction therapy with pemetrexed and cisplatin by extending survival , delaying disease progression , and maintaining quality of life ( QoL ) .